2 unknown. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Unknown 2 |
Follow SL VAXiGEN: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC. SL-T10, GX-I7, Pembrolizumab - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 | Unknown | SL VAXiGEN | 78 | 2022-10-17 | 2024-04-03 |
| Evaluate Tolerability and Safety of BD03 for Prevention of CMV and BKV Reactivation in Kidney Transplant Recipient BD03 - Cytomegalovirus Infections, Preventation of Cytomegalovirus Reactivation | Phase 1 | Unknown | SL VAXiGEN | 18 | 2018-04-27 | 2018-07-03 |
Cytomegalovirus Infections (1)
efineptakin alfa (1) · pembrolizumab (1)
South Korea (2)
Chang Wook Jeong, MD, phD (1) · Cheol Kwak, MD, phD (1)